Skip to content

Author

Yoshiyuki Suzuki

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

A phase II study combining radiotherapy and atezolizumab/nab-paclitaxel for inoperable or recurrent programmed death-ligand 1-positive triple-negative breast cancer: IMRad-Br study protocol and safety run-in.

BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expressions, with poor prognosis and limited treatment options. Studies have demonstrated the efficacy of immune checkpoint inhibitors (ICIs) combined w...

Hiroshi Ishiguro, N. Hoshi, Shin-Ei Noda et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.